Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review
M Maillard, F Le Louedec, F Thomas… - Expert Opinion on Drug …, 2020 - Taylor & Francis
Introduction: Platinum-derived drugs are commonly used for the treatment of solid tumors.
The differences in chemical structures of these molecules lead to different pharmacological …
The differences in chemical structures of these molecules lead to different pharmacological …
[PDF][PDF] Safe management of 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX)+ panitumumab in a patient with metastatic colorectal cancer undergoing hemodialysis …
E Filoni, V Musci, G Dibisceglia… - Precision Cancer …, 2023 - cdn.amegroups.cn
Background: Chemotherapy in metastatic colorectal cancer (mCRC) undergoing in
hemodialysis (HD) for end-stage renal disease (ESRD) remains an unsolved problem due to …
hemodialysis (HD) for end-stage renal disease (ESRD) remains an unsolved problem due to …
Neoadjuvant FOLFIRINOX Therapy for a Patient with Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Hemodialysis: Case Report.
ME Jao, KS Lee, S Jeong… - Journal of …, 2022 - search.ebscohost.com
BACKGROUND: Pancreatic cancer is among the leading causes of cancer deaths in the
United States. Resection remains the only cure for pancreatic cancer, which is available only …
United States. Resection remains the only cure for pancreatic cancer, which is available only …
Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis
DC Moore, KA Eagers, A Janes… - Journal of Oncology …, 2023 - journals.sagepub.com
Introduction Tafasitamab is an anti-CD19 monoclonal antibody indicated for the treatment of
relapsed/refractory diffuse large B-cell lymphoma to be given in combination with …
relapsed/refractory diffuse large B-cell lymphoma to be given in combination with …